81 related articles for article (PubMed ID: 17627421)
1. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.
Hindorf C; Chittenden S; Causer L; Lewington VJ; Mäcke HR; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):130-5. PubMed ID: 17627421
[TBL] [Abstract][Full Text] [Related]
2.
Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
[TBL] [Abstract][Full Text] [Related]
3. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
4. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Bodei L; Cremonesi M; Zoboli S; Grana C; Bartolomei M; Rocca P; Caracciolo M; Mäcke HR; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):207-16. PubMed ID: 12552338
[TBL] [Abstract][Full Text] [Related]
5. A five-compartment biokinetic model for
Jeremic MZ; Matovic MD; Krstic DZ; Pantovic SB; Nikezic DR
Med Phys; 2018 Dec; 45(12):5577-5585. PubMed ID: 30291717
[TBL] [Abstract][Full Text] [Related]
6. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
7. Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.
Van Binnebeek S; Baete K; Vanbilloen B; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Haustermans K; Van Cutsem E; Verbruggen A; Bogaerts K; Verslype C; Deroose CM
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1141-57. PubMed ID: 24668274
[TBL] [Abstract][Full Text] [Related]
8. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
9. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
10. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
12. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
Cremonesi M; Ferrari M; Zoboli S; Chinol M; Stabin MG; Orsi F; Maecke HR; Jermann E; Robertson C; Fiorenza M; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Aug; 26(8):877-86. PubMed ID: 10436201
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry of
Xu L; Meng Q; Yao X; Yang R; Zhang P; Li R; Wang F
Appl Radiat Isot; 2022 Jan; 179():109975. PubMed ID: 34741954
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 DOTATOC: first clinical results.
Otte A; Herrmann R; Heppeler A; Behe M; Jermann E; Powell P; Maecke HR; Muller J
Eur J Nucl Med; 1999 Nov; 26(11):1439-47. PubMed ID: 10552085
[TBL] [Abstract][Full Text] [Related]
15. Effect of image registration on 3D absorbed dose calculations in
Grassi E; Fioroni F; Berenato S; Patterson N; Ferri V; Braglia L; Filice A; Versari A; Iori M; Spezi E
Phys Med; 2018 Jan; 45():177-185. PubMed ID: 29472084
[TBL] [Abstract][Full Text] [Related]
16. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
Gupta SK; Singla S; Thakral P; Bal CS
Clin Nucl Med; 2013 Mar; 38(3):188-94. PubMed ID: 23412597
[TBL] [Abstract][Full Text] [Related]
18. Kidney dosimetry during
Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
20. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
Konijnenberg MW
Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]